Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 15/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 15/20 | 0.55 |
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504025 | 1.00 | LTB4R (0.55) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4504027 | 1.00 | LTB4R (0.55) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4352255 | 0.91 | LTB4R (0.63) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4352260 | 0.91 | LTB4R (0.63) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4507305 | 0.88 | LTB4R (0.47) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4507308 | 0.88 | LTB4R (0.47) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4507310 | 0.88 | LTB4R (0.47) | LTB4RLTB4R2RXRARARALMNA | |
| SCHEMBL4503385 | 0.80 | LTB4R (0.55) | LTB4RLTB4R2 | |
| SCHEMBL4503383 | 0.80 | LTB4R (0.55) | LTB4RLTB4R2 | |
| SCHEMBL4503389 | 0.80 | LTB4R (0.55) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638540-B2 | Benzofuran compound and medicinal composition containing the same | THE NEW INDUSTRY RESEARCH ORGANIZATION (JP) | 2009-12-29 | — | — | US | disclosed |
| US-20060194851-A1 | Benzofuran compound and medicinal composition containing the same | NEW INDUSTRY RESEARCH ORGANIZATION, THE (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1627873-A1 | BENZOFURAN COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | The New Industry Research Organization (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194851-A1 | Benzofuran compound and medicinal composition containing the same | LTB4R2, LTC4S, LTB4R | LTB4R 3/4885LTB4R2 1/4885RXRA 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.